Want to see SE:ASKER full AI Analyst Report?
Top Page
Asker Healthcare Group AB
(ASKER)
Select Model
Select Model
Rating:56Neutral
Price Target:
kr80.00
▼(-2.74% Downside)
Action:Reiterated
Date:07/22/26
The score is primarily driven by solid financial momentum (strong growth, improving profitability trends, and positive free cash flow), tempered by leverage and thin net margins. Technical indicators are mixed with weaker short-term trend, and valuation is a notable drag due to the high P/E and low yield.
Positive Factors
Revenue Growth
Sustained and accelerating top-line growth (38.6% in 2025) indicates expanding market share or successful commercial execution. Over a 2-6 month horizon this supports durable revenue momentum, provides capacity to invest in scale, and underpins margin and cash generation improvements.
Negative Factors
Elevated Leverage
Capital structure remains relatively leveraged for a low-net-margin distributor. Although leverage improved in 2025, the higher debt load increases refinancing, interest, and solvency risk, limiting strategic flexibility and amplifying downside in adverse industry cycles.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained and accelerating top-line growth (38.6% in 2025) indicates expanding market share or successful commercial execution. Over a 2-6 month horizon this supports durable revenue momentum, provides capacity to invest in scale, and underpins margin and cash generation improvements.
Read all positive factors
Asker Healthcare Group AB (ASKER) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr31.14B
Dividend YieldN/A
Average Volume (3M)1.96M
Price to Earnings (P/E)44.9
Beta (1Y)0.72
Revenue GrowthN/A
EPS GrowthN/A
CountrySE
Employees4,885
SectorGeneral
Sector StrengthN/A
IndustryMedical - Distribution
Share Statistics
EPS (TTM)1.78
Shares Outstanding383,706,480
10 Day Avg. Volume378,678
30 Day Avg. Volume1,960,693
Financial Highlights & Ratios
PEG Ratio2.05
Price to Book (P/B)4.74
Price to Sales (P/S)1.85
P/FCF Ratio42.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.83
Revenue Forecast (FY)kr19.06B
Asker Healthcare Group AB Business Overview & Revenue Model
Company Description
Asker Healthcare Group AB is a comprehensive provider of medical supplies, equipment, and related solutions, all designed to enhance patient care. Their broad product portfolio encompasses essential consumables such as protective items, infusion s...
How the Company Makes Money
null...
Asker Healthcare Group AB Financial Statement Overview
Summary
Income Statement
68
Positive
Balance Sheet
56
Neutral
Cash Flow
60
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 18.01B | 16.79B | 15.03B | 13.45B | 11.72B | 9.35B |
| Gross Profit | 6.98B | 6.05B | 5.88B | 4.52B | 3.78B | 2.61B |
| EBITDA | 1.96B | 2.09B | 1.47B | 1.12B | 1.12B | 670.00M |
| Net Income | 684.00M | 492.00M | 360.00M | 203.00M | 430.00M | 467.00M |
Balance Sheet | ||||||
| Total Assets | 17.83B | 16.77B | 13.12B | 11.33B | 10.23B | 7.36B |
| Cash, Cash Equivalents and Short-Term Investments | 777.00M | 884.00M | 490.00M | 391.00M | 211.00M | 494.00M |
| Total Debt | 6.48B | 5.81B | 5.96B | 4.97B | 4.74B | 3.93B |
| Total Liabilities | 10.81B | 10.19B | 9.62B | 8.29B | 7.44B | 5.54B |
| Stockholders Equity | 6.98B | 6.55B | 3.47B | 3.02B | 2.76B | 1.79B |
Cash Flow | ||||||
| Free Cash Flow | 995.00M | 738.00M | 879.00M | 901.00M | 853.00M | 258.00M |
| Operating Cash Flow | 1.52B | 1.33B | 1.23B | 1.05B | 976.00M | 382.00M |
| Investing Cash Flow | -2.32B | -2.91B | -1.46B | -783.00M | -1.86B | -843.00M |
| Financing Cash Flow | 260.00M | 2.02B | 305.00M | -83.00M | 572.00M | 619.00M |
Asker Healthcare Group AB Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | kr19.38B | 32.27 | 10.82% | 0.95% | 0.82% | 77.45% | |
65 Neutral | kr7.52B | 19.41 | 5.03% | 3.60% | -3.08% | -10.70% | |
64 Neutral | kr35.03B | 38.00 | ― | 1.01% | 5.73% | 90.34% | |
56 Neutral | kr31.14B | 44.94 | ― | ― | ― | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
53 Neutral | kr20.04B | -38.63 | -6.37% | 5.11% | -7.22% | -319.36% | |
51 Neutral | kr12.33B | -2.45 | -53.29% | 0.80% | -4.21% | -1194.93% |
* General Sector Average
SE:ASKER
Asker Healthcare Group AB
80.00
-18.30
-18.62%
SE:EKTA.B
Elekta AB
52.30
7.35
16.36%
SE:VITR
Vitrolife AB
90.30
-43.52
-32.52%
SE:MCOV.B
Medicover AB
235.00
-36.17
-13.34%
SE:ALIF.B
AddLife AB
157.80
-3.62
-2.24%
SE:ARJO.B
Arjo AB
27.56
-3.96
-12.56%
Asker Healthcare Group AB Corporate Events
Asker Healthcare Delivers Double-Digit Growth and Expands European Reach
Jul 21, 2026
Asker Healthcare Group reported another quarter of steady expansion, with net sales rising 18 percent to SEK 4.69 billion and adjusted EBITA up 24 percent, lifting the margin to 10.0 percent. Profit for the quarter jumped to SEK 225 million and ea...
Asker Healthcare Group Sets Webcast for Q2 2026 Interim Report
Jul 7, 2026
Asker Healthcare Group will release its interim report for the first half of 2026 on 21 July and follow up with a webcast presentation later that morning for investors, analysts and media. Chief executive Johan Falk and chief financial officer Tho...
Asker Healthcare boosts Irish footprint with Murray Surgical acquisition
Jul 3, 2026
Asker Healthcare Group, a major European provider of medical products and solutions, has expanded its portfolio through the acquisition of Murray Surgical, a specialist distributor serving hospitals across Ireland. Murray Surgical, founded in 1978...
Asker Healthcare Drops Kirstine Hardam Deal, Refocuses M&A Pipeline
Jun 8, 2026
Asker Healthcare Group, a European provider of medical products and solutions that acquires and develops leading local healthcare companies, operates in 19 countries with over 5,000 employees and SEK 17 billion in revenue, focusing on improving pa...
Asker’s Chair Receives Shareholder-Financed Call Options from Major Owner
Jun 3, 2026
Asker Healthcare Group, a European provider of medical products and solutions to caregivers and patients, operates through a network of acquired and built companies across 19 countries, focusing on improving patient outcomes and lowering total hea...
Asker Healthcare Shareholders Approve Dividend, New Chair and Expanded Capital Mandate
May 7, 2026
Asker Healthcare Group AB held its Annual General Meeting in Stockholm, where shareholders approved the 2025 financial statements and a dividend of SEK 0.39 per share, with payment scheduled for mid-May 2026. The directors and CEO were discharged ...
Asker Healthcare starts 2026 with strong growth, margin gains and new deals
May 6, 2026
Asker Healthcare Group reported a strong first quarter of 2026, with net sales up 13% to SEK 4.52 billion and organic growth of 5%. Adjusted EBITA rose 21% with an 8% organic increase, lifting the adjusted EBITA margin to 9.8%, while profit for th...
Asker Healthcare Group Schedules Webcast for Q1 2026 Interim Report
Apr 22, 2026
Asker Healthcare Group will release its interim report for the first quarter of 2026 on 6 May and will host a webcast presentation the same day for investors, analysts and media. The online event, led by CEO Johan Falk and CFO Thomas Moss, will in...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.